Literature DB >> 30255436

The ALPPS procedure: hepatocellular carcinoma as a main indication. An Italian single-center experience.

Giovanni Vennarecci1, Daniele Ferraro2, Antonella Tudisco2, Giovanni Battista Levi Sandri2, Nicola Guglielmo2, Giammauro Berardi2, Isabella Sperduti3, Giuseppe Maria Ettorre2.   

Abstract

The ALPPS is a technique that allows achieving hepatic resection by a rapid future liver remnant hypertrophy. The aim of this study was to report the experience of an Italian center with ALPPS in patients with liver tumors. A retrospective analysis of patients undergoing ALPPS between 2012 and 2017 was performed. Patients' characteristics and disease presentation, increase in future liver remnant (FLR) as well as intraoperative and postoperative short- and long-term outcomes were evaluated. A total of 24 patients underwent the ALPPS procedure: 17 procedures for hepatocarcinoma (HCC), 5 for colorectal liver metastases (CRLM), 1 for cholangiocarcinoma (CC) and 1 for Merkel Cell Carcinoma liver metastasis (MCCLM). Macrovascular invasion (MVI) was recorded in 10 (41.6%) patients: 8 (33.3%) patients with HCC had invasion of portal vein (5), middle hepatic vein (2) and inferior vena cava (1). One patient with CRLM had involvement of middle hepatic vein and one patient with CC had involvement of right portal vein and middle hepatic vein. A p-ALPPS in 14 cases (58.3%), 10 t-ALPPS (41.6%) and hanging maneuver in 19 patients (80%) were performed. Median postoperative stay was 26 days (range 16-68 days). 90-day mortality was 8.3% (two patients, one with CC and one with HCC), 90-day mortality for HCC was 5.8%. After stage 1, we counted 15 complications all of grade I; after stage 2 the number of complications was increased to 37:33 were of grade I and 4 were of grade IV. R0 resection was achieved in all patients with 100% oncology feasibility. After a median follow-up of 10 months (range 2-54), disease recurrence has been recorded in 6 patients with HCC and in 2 with CRLM. Eleven patients died, nine affected by HCC, one by CRLM, and one by CC. 2-years OS and disease-free survival (DFS) for the entire group were 47.3% and 47.5%, respectively. Concerning patients operated on for HCC, the 2-years OS and DFS were 38.5% and 60%, respectively. The ALPPS procedure is an interesting approach for large primary or secondary liver tumor with small FLR above all for large HCC associated with MVI, with acceptable OS and DFS.

Entities:  

Keywords:  ALPPS; Cirrhosis; HCC; Hepatic resection; Metastases

Mesh:

Year:  2018        PMID: 30255436     DOI: 10.1007/s13304-018-0596-3

Source DB:  PubMed          Journal:  Updates Surg        ISSN: 2038-131X


  32 in total

1.  EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma.

Authors: 
Journal:  J Hepatol       Date:  2012-04       Impact factor: 25.083

2.  Is the liver kinetic growth rate in ALPPS unprecedented when compared with PVE and living donor liver transplant? A multicentre analysis.

Authors:  Kristopher P Croome; Roberto Hernandez-Alejandro; Maile Parker; Julie Heimbach; Charles Rosen; David M Nagorney
Journal:  HPB (Oxford)       Date:  2015-02-28       Impact factor: 3.647

3.  Performing the ALPPS Procedure by Anterior Approach and Liver Hanging Maneuver.

Authors:  Giovanni Vennarecci; Giovanni Battista Levi Sandri; Giuseppe Maria Ettorre
Journal:  Ann Surg       Date:  2016-01       Impact factor: 12.969

4.  A room for the alpps procedure in patients with HCC.

Authors:  Giovanni Vennarecci; Gian Luca Grazi; Roberto Santoro; Giuseppe Maria Ettorre
Journal:  Int J Surg       Date:  2014-12-09       Impact factor: 6.071

5.  Sorafenib vs surgical resection for hepatocellular carcinoma with macrovascular invasion: A propensity score analysis.

Authors:  Charlotte E Costentin; Thomas Decaens; Alexis Laurent; Jean-Charles Nault; Bernard Paule; Christian Letoublon; Alain Luciani; Julien Calderaro; René Adam; Ivan Bricault; Giuliana Amaddeo; Daniel Cherqui; Ariane Mallat; Didier Samuel; Christophe Duvoux; Nathalie Ganne-Carrié; Françoise Roudot-Thoraval; Eric Vibert
Journal:  Liver Int       Date:  2017-07-13       Impact factor: 5.828

6.  Impact of portal vein embolization on long-term survival of patients with primarily unresectable colorectal liver metastases.

Authors:  D A Wicherts; R J de Haas; P Andreani; D Sotirov; C Salloum; D Castaing; R Adam; D Azoulay
Journal:  Br J Surg       Date:  2010-02       Impact factor: 6.939

7.  ALPPS offers a better chance of complete resection in patients with primarily unresectable liver tumors compared with conventional-staged hepatectomies: results of a multicenter analysis.

Authors:  Erik Schadde; Victoria Ardiles; Ksenija Slankamenac; Christoph Tschuor; Gregory Sergeant; Nadja Amacker; Janine Baumgart; Kris Croome; Roberto Hernandez-Alejandro; Hauke Lang; Eduardo de Santibaňes; Pierre-Alain Clavien
Journal:  World J Surg       Date:  2014-06       Impact factor: 3.352

8.  Technical note on ALPPS for a patient with advanced hepatocellular carcinoma associated with invasion of the inferior vena cava.

Authors:  Tan To Cheung; Tiffany Cho Lam Wong; See Ching Chan
Journal:  Hepatobiliary Pancreat Dis Int       Date:  2016-06

9.  ALPPS for primary and secondary liver tumors.

Authors:  Giovanni Vennarecci; Gian Luca Grazi; Isabella Sperduti; Elisa Busi Rizzi; Emanuele Felli; Mario Antonini; Giampiero D'Offizi; Giuseppe Maria Ettorre
Journal:  Int J Surg       Date:  2016-04-22       Impact factor: 6.071

10.  Analysis of the efficacy of portal vein embolization for patients with extensive liver malignancy and very low future liver remnant volume, including a comparison with the associating liver partition with portal vein ligation for staged hepatectomy approach.

Authors:  Junichi Shindoh; Jean-Nicolas Vauthey; Giuzeppe Zimmitti; Steven A Curley; Steven Y Huang; Armeen Mahvash; Sanjay Gupta; Michael J Wallace; Thomas A Aloia
Journal:  J Am Coll Surg       Date:  2013-04-28       Impact factor: 6.113

View more
  4 in total

1.  Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) for advanced hepatocellular carcinoma with macrovascular invasion.

Authors:  Giammauro Berardi; Nicola Guglielmo; Marco Colasanti; Roberto Luca Meniconi; Stefano Ferretti; Germano Mariano; Sofia Usai; Marco Angrisani; Alessandra Pecoraro; Alessio Lucarini; Camilla Gasparoli; Giuseppe Maria Ettorre
Journal:  Updates Surg       Date:  2022-03-19

2.  Acute kidney injury after associating liver partition and portal vein ligation for staged hepatectomy for hepatocellular carcinoma: two case reports and a literature review.

Authors:  Hanchun Huang; Xin Lu; Huayu Yang; Yiyao Xu; Xinting Sang; Haitao Zhao
Journal:  Ann Transl Med       Date:  2019-12

3.  In situ split plus portal vein ligation (ISLT) - a salvage procedure following inefficient portal vein embolization to gain adequate future liver remnant volume prior to extended liver resection.

Authors:  Nadja Lehwald-Tywuschik; Sascha Vaghiri; Jan Schulte Am Esch; Salman Alaghmand; Yan Klosterkemper; Lars Schimmöller; Anja Lachenmayer; Hany Ashmawy; Andreas Krieg; Stefan A Topp; Alexander Rehders; Wolfram Trudo Knoefel
Journal:  BMC Surg       Date:  2020-04-06       Impact factor: 2.102

Review 4.  A better route to ALPPS: minimally invasive vs open ALPPS.

Authors:  Kawka Michal; Mak Sau; Gall M H Tamara; Jiao R Long
Journal:  Surg Endosc       Date:  2020-04-09       Impact factor: 4.584

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.